Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Recombinant human erythropoietin.

M H Schwenk1, C E Halstenson

  • 1Drug Evaluation Unit, Hennepin County Medical Center, Minneapolis, MN 55415.

DICP : the Annals of Pharmacotherapy
|July 1, 1989
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Two randomized, double-blind, placebo-controlled, dose-escalation phase 1 studies evaluating BTH1677, a 1, 3-1,6 beta glucan pathogen associated molecular pattern, in healthy volunteer subjects.

Investigational new drugs·2016
Same author

Rapid, high-dose intravenous iron sucrose therapy in 2 Jehovah's Witness patients with severe anemia, iron deficiency and chronic kidney disease.

Clinical nephrology·2004
Same author

The influence of dialyzer type on serum albumin in hemodialysis patients.

Clinical nephrology·2004
Same author

Pharmacokinetics and blood pressure response of losartan in end-stage renal disease.

Clinical pharmacokinetics·2000
Same author

Pharmacokinetics of flutamide in patients with renal insufficiency.

British journal of clinical pharmacology·1999
Same author

Effect of angiotensin-converting enzyme inhibitors on response to erythropoietin therapy in chronic dialysis patients.

American journal of nephrology·1998

Recombinant human erythropoietin (r-hEPO) effectively treats anemia in chronic renal disease patients, improving quality of life. Careful monitoring is essential to manage potential side effects like hypertension and thrombosis.

Area of Science:

  • Nephrology
  • Hematology
  • Pharmacology

Background:

  • Anemia is a common complication of chronic renal failure, primarily due to erythropoietin deficiency.
  • Erythropoietin, produced by the kidneys, regulates red blood cell production in the bone marrow.

Purpose of the Study:

  • To present the clinical pharmacology, efficacy, safety, and tolerance of recombinant human erythropoietin (r-hEPO).
  • To evaluate the effectiveness of r-hEPO in treating anemia associated with chronic renal disease.

Main Methods:

  • Review of four major clinical studies on r-hEPO in anemia of chronic renal disease.
  • Analysis of efficacy, safety, and tolerance data, including adverse reactions and resistance factors.

Main Results:

Related Experiment Videos

  • r-hEPO demonstrated efficacy in correcting anemia and improving patient well-being, exercise tolerance, and cognitive function.
  • Identified potential toxicities including hypertension, iron deficiency, thrombosis, and bone pain.
  • Factors contributing to resistance include iron deficiency, aluminum toxicity, and inflammation.

Conclusions:

  • r-hEPO is an effective treatment for anemia in chronic renal disease.
  • Careful management of hematocrit, anticoagulation, and diet can minimize adverse reactions.
  • Potential future applications in other anemias warrant further investigation.